Multiple Myeloma and EasyM Resource Centre.
Featured
Comparison of EasyM Clonotypic Mass Spectrometry and EuroFlow MRD in Multiple Myeloma
Iain Rogers2025-03-04T10:05:19-05:00March 3rd, 2025|Publication|
Mass Spectrometry Testing in Multiple Myeloma
Iain Rogers2025-02-24T16:20:23-05:00February 11th, 2025|Articles|
M-spike and Multiple Myeloma
Iain Rogers2025-02-24T16:20:40-05:00February 5th, 2025|Articles|
Publications, Posters & Case Studies
Jenna Kerry2025-10-30T13:42:02-04:00
Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions
Jenna Kerry2025-10-30T13:42:02-04:00October 30th, 2025|Publication|
Jenna Kerry2025-06-11T15:55:48-04:00
Discontinuation of Maintenance Therapy in Multiple Myeloma Guided by Multimodal Measurable Residual Disease Negativity (MRD2STOP)
Jenna Kerry2025-06-11T15:55:48-04:00June 11th, 2025|Publication|
Jenna Kerry2025-05-21T11:04:11-04:00
Minimal Residual Disease as a Primary Endpoint in Multiple Myeloma
Jenna Kerry2025-05-21T11:04:11-04:00May 21st, 2025|Publication|
Articles
Press & News
Iain Rogers2025-03-21T11:58:31-04:00
ASH 2022 | Dr. Ravi Vij – VJ HemeOnc
Iain Rogers2025-03-21T11:58:31-04:00December 15th, 2022|News|